Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

GlaxoSmithKline avoided rebate obligations tied to the Flovent price inflation, the lawsuit says. "It raised the price so much that, with the removal of the rebate cap, GSK was faced with the ...

Pharmaceuticals giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drugs pipeline. It came as the boss of the London-listed firm cheered an “excellent ...

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

GSK has increased its long-term sales guidance amid hopes for a boost from new speciality medicines (Andy Buchanan/PA) Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales ...

Something seems to be going awry with GlaxoSmithKline's game plan for its ... over £1.09 billion and down 19 per cent in the US. GSK chief executive Andrew Witty told investors yesterday that ...